Article
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.
Science translational medicine - 11 Apr 2018
Carvajal Luis A, Neriah Daniela Ben, Senecal Adrien, Benard Lumie, Thiruthuvanathan Victor, Yatsenko Tatyana, Narayanagari Swathi-Rao, Wheat Justin C, Todorova Tihomira I, Mitchell Kelly, Kenworthy Charles, Guerlavais Vincent, Annis D Allen, Bartholdy Boris, Will Britta, Anampa Jesus D, Mantzaris Ioannis, Aivado Manuel, Singer Robert H, Coleman Robert A, Verma Amit, Steidl Ulrich
Abstract excerpt
The tumor suppressor p53 is often inactivated via its interaction with endogenous inhibitors mouse double minute 4 homolog (MDM4 or MDMX) or mouse double minute 2 homolog (MDM2), which are frequently overexpressed in patients with acute myeloid leukemia (AML) and other cancers. Pharmacological disruption of both of these interactions has long been sought after as an attractive strategy to fully restore...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.